Angiotensin Receptor Blocker After TAVR in Severe Aortic Stenosis With Left Ventricular Hypertrophy (ARBITAR)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 632 participants.

Also called NCT07735130

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 632 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07735130
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07735130. Randomized; no masking; primary purpose treatment. Start 2026-08-15 (anticipated); primary completion 2030-06-15 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Angiotensin Receptor Blocker After TAVR in Severe Aortic Stenosis With Left Ventricular Hypertrophy (ARBITAR)
Acronym
ARBITAR
Condition
Left Ventricular Hypertrophy
Condition
Severe Aortic Stenosis
Intervention (Drug)
Angiotensin Receptor Blocker (ARB)
Lead sponsor
Seoul National University Hospital (class: other)
Collaborator
Samjin Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct07735130
Content hash
6e8976327086c2bdcd0a03fef907df3a0f0a1903f7786b2862b46ce258eef1b6